Jordyn Sava is an assistant editor for Targeted Oncology.
Voruciclib +/- Venetoclax Yeilds Promising Efficacy in AML or B-Cell MalignanciesMay 25th 2023
When used as a monotherapy or in combination with venetoclax, voruciclib was generally well tolerated and showed an encouraging preliminary efficacy signal in patients with acute myeloid leukemia or B-cell malignancies.
Oncologists Back Legislation to Help Improve Access to Biomarker TestingMay 24th 2023
Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.
FDA Grants Orphan Drug Designation to Mitazalimab for Pancreatic CancerMay 23rd 2023
Mitazalimab has received an orphan drug designation from the FDA and is currently being investigated in the OPTIMIZE-1 trial in combination with modified FOLFIRINOX for the treatment of patients with pancreatic cancer.
Cabozantinib With Nivolumab and Ipilimumab Prolongs PFS in Renal Cell CarcinomaMay 22nd 2023
While cabozantinib, nivolumab, and ipilimumab resulted in a longer progression-free survival among patients with renal cell carcinoma vs nivolumab and ipilimumab alone, more adverse events were observed with the combination.
Behind the FDA Approval: Subcutaneous Epcoritamab for R/R DLBCLMay 19th 2023
In an interview with Targeted Oncology, Tycel Phillips, MD, discussed what led to the FDA approval of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma and how it adds to the current treatment landscape.
What is Optimal Donor Type for Patients With Cancer in Need of SCT?May 19th 2023
In an interview with Targeted Oncology, Salman Fazal, MD, discussed differences between older matched sibling donors vs younger unrelated donors in stem cell transplants and donor preferences at his institution for patients with cancer.
FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic CancerMay 19th 2023
Rucosopasem manganese is being investigated in the phase 1/2 GRECO-1 and phase 2b GRECO-2 trials in combination with stereotactic body radiation therapy for the treatment of patients withlj non–small cell lung cancer and pancreatic cancer.
Venetoclax and Obinutuzumab With/Without Ibrutinib Improves Efficacy in CLLMay 17th 2023
Adult patients with chronic lymphocytic leukemia had significantly better minimal residual disease and progression-free survival results when treated with venetoclax and obinutuzumab or venetoclax, obinutuzumab, and ibrutinib vs standard chemoimmunotherapy
FDA Grants SGX301 a Type A Meeting for the Treatment of CTCLMay 15th 2023
The FLASH study and compatibility study of SGX301 led to promising safety and efficacy responses for the treatment of cutaneous T-cell lymphoma. Now, the FDA has granted a type A meeting to discuss the design of a second trial of SGX301.
Roxadustat Misses Efficacy End Point in Phase 3 MDS StudyMay 12th 2023
The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.
PD-1 Inhibitors Plus Anti-CD19-CAR T Cells May Be Safe for R/R DLBCLMay 12th 2023
A study of patients with relapsed/refractory diffuse large B-cell lymphoma has showed that continuous administration of PD-1 inhibitors as a maintenance treatment may be feasible to maintain the efficacy of anti-CD19-CAR T cells.